China Biologic Products, Inc. (NASDAQ: CBPO), is one of the largest non-state-owned fully integrated plasma-based biopharmaceutical companies in China. Our core capabilities include plasma collection, research and development, production, and commercialization of biopharmaceutical products.
We have a strong product portfolio with over 20 different dosage forms of plasma products in three major classes, including human albumin, immunoglobulin for intravenous injection and coagulation factor products, and have new products under development to drive our future growth. We are constantly at work to enhance our research and development and technological capabilities to create new products and to improve our existing products and processes.
Our headquarters is based in the city of Beijing. We manufacture through our majority-owned subsidiaries, Shandong Taibang Biological Products Co.,Ltd and Guizhou Taibang Biological Products Co., Ltd., and have a minority equity investment in Xi’an Huitian Blood Products Co.,Ltd. We also own one pharmaceutical distribution company, one pharmaceutical research center, and 12 captive plasma collection centers.
We sell directly to over 1,000 hospitals and inoculation centers in China and seek to reduce the use of independent distributors.
Our company was founded in 2002 and was listed on NASDAQ in 2009. Since 2009, we have been ranked three times as Asia’s “200 Best under a Billion” in the annual list compiled by Forbes Magazine.